ANAPTYSBIO, INC 8-K

What Happened
AnaptysBio, Inc. (ANAB) announced on May 11, 2026 that its Board appointed Christopher M. Murphy as Chief Financial Officer, effective that same date, and that Owen Hughes was appointed a Class I director effective May 11, 2026. The company filed the 8-K to disclose these management and board changes.

Key Details

• Christopher M. Murphy named CFO effective May 11, 2026; previously CFO at Third Harmonic Bio (Jan 2024–Dec 2025) and held senior roles at Horizon Therapeutics and JMP Securities. Murphy will serve as an independent contractor under a consulting agreement.
• Consulting pay and incentives: $42,916.66 monthly consulting fee; annual target cash bonus opportunity up to 40% of total annual consulting fees (prorated if partial year).
• Equity and vesting: Murphy to receive RSU award valued at $1,750,000: 1/4 vests on the first anniversary and the remainder vests in equal annual installments over the next three years.
• Termination protections: If terminated without cause (no corporate transaction), Murphy may receive 9 months continued consulting fees (subject to a release). If terminated without cause in connection with or within 13 months after a “corporate transaction,” he may receive 12 months consulting fees, a lump-sum cash amount related to the Bonus (including a prorated component), and full vesting of outstanding equity awards. Full consulting agreement to be filed as an exhibit to the company’s 10-Q for the quarter ended June 30, 2026.
• Board appointment: Owen Hughes appointed Class I director effective May 11, 2026; received 11,250 RSUs that vest over three years and has the company’s standard indemnification agreement. No related-party issues disclosed.

Why It Matters
A CFO change is material for investors because it affects financial leadership and execution of strategy. The consulting agreement shows the company is compensating the CFO largely with equity and performance-based pay, which aligns incentives but also creates potential dilution from the $1.75M RSU grant. The severance and change-in-control protections could have cash and equity consequences in a corporate transaction. The director addition expands board expertise; both appointments were disclosed without related-party transactions.